Dalton Einhorn
Profile
Prior to joining JJDC, Mr. Einhorn was a Principal with Latterell Venture Partners, a healthcare venture capital firm.
His experience also includes 11 years in the pharmaceutical industry.
At Hoffmann-La Roche, his roles included Product Manager for Demadex and Rocephin.
With Daiichi-Sankyo, Mr. Einhorn held various global pre-launch commercialization leadership roles.
Mr. Einhorn also spent four years in the Mergers & Acquisitions group of Credit Suisse.
Mr. Einhorn received an MBA degree from Yale School of Management and a bachelor’s degree from Drew University.
Former positions of Dalton Einhorn
| Companies | Position | End |
|---|---|---|
ViaCyte, Inc.
 ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Director/Board Member | - |
| GENOCEA BIOSCIENCES, INC. | Director/Board Member | - |
Johnson & Johnson Innovation - JJDC, Inc.
 Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | Private Equity Investor | - |
| DAIICHI SANKYO CO., LTD. | Corporate Officer/Principal | - |
Novo Nordisk, Inc.
 Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Corporate Officer/Principal | - |
Training of Dalton Einhorn
| Yale University | Masters Business Admin |
| Drew University | Undergraduate Degree |
Experiences
Positions held
Linked companies
| Listed companies | 2 |
|---|---|
| DAIICHI SANKYO CO., LTD. | Health Technology |
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Latterell Venture Partners
 Latterell Venture Partners Investment ManagersFinance Latterell Venture Partners (Latterell Venture Partners) is a venture capital firm founded in 2001 by Pat Latterell. The firm is headquartered in San Ramon, California. | Finance |
Novo Nordisk, Inc.
Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Health Technology |
Johnson & Johnson Innovation - JJDC, Inc.
Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | Finance |
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Dalton Einhorn
